🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
23.22
-1.08 (-4.44%)
At close: Nov 20, 2026, 4:00 PM EST
23.17
-0.05 (-0.22%)
After-hours: Nov 20, 2026, 7:30 PM EST

Damora Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Damora Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $46.78. The average 1-year stock price forecast is 101.46% higher than the current stock price, while the lowest is $40 (+72.27%) and the highest is $59 (+154.09%).

Price Target: $46.78 (+101.46%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$40$46.78$45$59
Change+72.27%+101.46%+93.80%+154.09%

Analyst Ratings

The average analyst rating for Damora Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy899999
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total91010101010

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Wedbush
Wedbush
Buy
Maintains
$40
BuyMaintains$40+72.27%Nov 18, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$45
BuyMaintains$45+93.80%Nov 16, 2026
Guggenheim
Guggenheim
Buy
Maintains
$60 → $59
BuyMaintains$60 → $59+154.09%Nov 6, 2026
Leerink Partners
Leerink Partners
Buy
Maintains
$51
BuyMaintains$51+119.64%Nov 5, 2026
RBC Capital
RBC Capital
Buy
Maintains
$40
BuyMaintains$40+72.27%Nov 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.90
EPS Next Year
-2.17
from -1.90
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-52.23M-61.21M-36.46M-16.90M-36.56M-140.30M
Net Income
-51.75M-61.62M-38.35M-21.44M-209.84M-125.55M
EPS
------1.90
Free Cash Flow
------125.00M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.60
Avg-1.90
Low-2.34

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-